Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC).
Cobolimab (0.0001-10 nM; 3 d) promotes TIM-3 internalization in a dose dependent manner in pre-activated T cells with an IC50 value of 0.4464 nM[3].Cobolimab (20 µg/mL; 24 h) significantly increases CD8+ T cell content by inhibiting TIM-3[4].
References:
[1]. Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022. [2]. Markham A. Dostarlimab: First Approval. Drugs. 2021 Jul;81(10):1213-1219.
[3]. Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. Antib Ther. 2020 Nov 9;3(4):227-236.
[4]. Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med. 2021 Sep;9(18):1447.